---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-283698"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:02:29.382867+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lantheus enters two license/collaboration deals with POINT for up to $1.87B in milestones, $260M upfront

## Summary
- Upfront cash: $250M for PNT-2002 (PSMA therapy) and $10M for PNT-2003 (SSTR therapy); combined potential milestones ~$1.87B.
- PNT-2002 targets PSMA for metastatic castrate-resistant prostate cancer; POINT responsible for clinical development.
- PNT-2003 targets SSTR-positive neuroendocrine tumors; Lantheus leads regulatory filings and commercialization post-approval.
- Royalties: 20% PNT-2002 net sales after $500M cumulative gross profit; 15% PNT-2003 net sales.
- Closing subject to HSR review; outside date June 30, 2023 (extendable by Lantheus to Aug 30, 2023).

## SEC filing metadata
- accession: 0001193125-22-283698
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/0001193125-22-283698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/d378760d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-283698
- JSON: https://secwatch.observer/filing/0001193125-22-283698.json
- Plain text: https://secwatch.observer/filing/0001193125-22-283698.txt

## Key facts
- Material Agreements
  Lantheus Holdings, Inc. entered into PNT-2002 License Agreement with POINT Biopharma Global Inc. valued at Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto (effective 2022-11-11).
  - Action: entry
  - Agreement: license
  - Counterparty: POINT Biopharma Global Inc.
  - Value: Upfront cash payment of $250 million; potential milestone payments up to $281 million; sales milesto
  - Effective: 2022-11-11
  source text: On November 11, 2022, Lantheus Two, LLC (“Lantheus Two”), an indirect wholly owned subsidiary of Lantheus Holdings, Inc. (the “Company”), entered into a license and collaboration agreement (the “PNT-2002 License Agreement”) with an affiliate of POINT Biopharma Global Inc. (“POINT”), to co-develop and commercialize PNT-2002, a prostate-specific membrane antigen-targeted radiopharmaceutical therapy for the treatment of metastatic castrate-resistant prostate cancer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1521036/000119312522283698/0001193125-22-283698-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.